Search results
Showing 751 to 800 of 1958 results for news
Find out more about NICE technology appraisals advisory committee D members
Find out more about NICE technology appraisals advisory committee D members
Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.
The guidance development timeline
Training and development opportunities at NICE
Training and development opportunities at NICE
Online help programme recommended for people with eating disorders
An online therapy programme can be used to help people aged 16 and over with eating disorders whilst they wait for specialist NHS treatment, an independent NICE has said.
This quality standard covers identifying, assessing and managing chronic liver disease in children, young people and adults, and cirrhosis in young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS152Show all sections
Sections for QS152
- Quality statements
- Quality statement 1: Advice on physical activity, diet and alcohol
- Quality statement 2 (developmental): Testing for advanced liver fibrosis
- Quality statement 3 (developmental): Non-invasive testing for cirrhosis
- Quality statement 4: Surveillance for hepatocellular carcinoma
- Quality statement 5: Prophylactic intravenous antibiotics for upper gastrointestinal bleeding
- Update information
- About this quality standard
Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)
NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .
Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis (MIB93)
NICE has developed a medtech innovation briefing (MIB) on the Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis .
Early value assessment (EVA) guidance on digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD.
AcQMap for mapping the heart atria to target ablation treatment for arrhythmias (MIB246)
NICE has developed a medtech innovation briefing (MIB) on AcQMap for mapping the heart atria to target ablation treatment for arrhythmias .
Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders
Chronic anal fissure: botulinum toxin type A injection (ESUOM14)
Summary of the evidence on botulinum toxin type A injection for treating chronic anal fissure to inform local NHS planning and decision-making
This guide provides an overview of the principles and methods of health technology assessment and appraisal within the context of the NICE appraisal process
Dupilumab for treating moderate to severe prurigo nodularis (TA955)
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe prurigo nodularis in adults when systemic treatment is suitable.
Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)
Evidence-based recommendations on risankizumab (Skyrizi) for previously treated moderately to severely active Crohn's disease in people 16 years and over.
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858)
Evidence-based recommendations on lenvatinib (Kisplyx) with pembrolizumab (Keytruda) for untreated advanced renal cell carcinoma in adults.
Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)
Evidence-based recommendations on talimogene laherparepvec (Imlygic) for treating unresectable metastatic melanoma in adults when systemically administered immunotherapies are not suitable.
Evidence-based recommendations on selpercatinib (Retsevmo) for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults.
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.
Tivozanib for treating advanced renal cell carcinoma (TA512)
Evidence-based recommendations on tivozanib (Fotivda) for treating advanced renal cell carcinoma in adults.
Bioresorbable stent implantation to treat coronary artery disease (HTG633)
Evidence-based recommendations on bioresorbable stent implantation to treat coronary artery disease in adults. This involves implanting a stent (small tube) into a narrowed artery to widen it.
View recommendations for HTG633Show all sections
Evidence-based recommendations on percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure in adults. This involves putting a small electronic pressure sensor into the pulmonary artery to measure blood pressure.
View recommendations for HTG599Show all sections
Evidence-based recommendations on percutaneous insertion of craniocaudal expandable implants for vertebral compression fracture in adults. This involves inserting an implant into the spine to restore the vertebral height.
Middle meningeal artery embolisation for chronic subdural haematomas (HTG706)
Evidence-based recommendations on middle meningeal artery embolisation for chronic subdural haematomas. This involves injecting particles into the middle meningeal artery to block it.
View recommendations for HTG706Show all sections
This process and methods guide has been developed to help guidance‑producing centres make research recommendations. It describes a step-by-step approach to identifying uncertainties, formulating research recommendations and research questions, prioritising them and communicating them to the NICE Science Policy and Research (SP&R) team, researchers, and funders
This guide gives an overview of the process for developing evidence summaries. Evidence summaries provide advice but do not include recommendations and are not formal NICE guidance
This guideline covers rehabilitation after stroke for over 16s. It aims to ensure people are assessed for common problems and conditions linked to stroke, and get the care and therapy they need. It includes recommendations on the organisation and delivery of rehabilitation in hospital and the community.
We provide an advisory service for international health organisations, ministries and government agencies whose task is to improve evidence-based decision making in health and social care.
Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)
Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of renal cell carcinoma in adults.
Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)
Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C in adults.
Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)
Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.
Urinary incontinence in neurological disease: assessment and management (CG148)
This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.
Healthy start vitamins: special report on cost effectiveness (ECD5)
This document describes a special report on the cost effectiveness of moving the Healthy Start vitamin programme from the current targeted offering to a universal offering
NICE has developed a medtech innovation briefing (MIB) on The Insides System for managing intestinal failure .
Unintentional injuries in the home: interventions for under 15s (PH30)
This guideline covers home safety assessments, supplying and installing safety equipment and providing education and advice. It aims to prevent unintentional injuries among all children and young people aged under 15 but, in particular, those living in disadvantaged circumstances.
View recommendations for PH30Show all sections
Sections for PH30
- Overview
- Recommendations
- Public health need and practice
- Considerations
- Recommendations for research
- References
- Appendix A: Membership of the Public Health Interventions Advisory Committee (PHIAC), the NICE project team and external contractors
- Appendix B: Summary of the methods used to develop this guidance
The PLASMA system for transurethral resection and haemostasis of the prostate (HTG563)
Evidence-based recommendations on the PLASMA system for transurethral resection and haemostasis of the prostate.
Antimicrobial prescribing: meropenem with vaborbactam (ES21)
Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making
Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars
More than 7,000 people in England will now be able to access to a life-extending treatment for advanced bowel cancer.
We estimate the costs or savings (resource impact) associated with technologies and guidelines so you can plan for and implement guidance.
Following the government’s 10 Year Health Plan for England, we're strengthening our role in getting the best healthtech, including digital tools, diagnostics and medical devices, to patients.
Endo-SPONGE for treating low rectal anastomotic leak (HTG605)
Evidence-based recommendations on Endo-SPONGE for treating low rectal anastomotic leak.
Late stage assessment (LSA) guidance on transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis.
View recommendations for HTG757Show all sections
This quality standard covers assessing and managing motor neurone disease, including care, support and planning after diagnosis. It describes high-quality care in priority areas for improvement.
View quality statements for QS126Show all sections
Sections for QS126
- Quality statements
- Quality statement 1: Information and support at diagnosis
- Quality statement 2: Respiratory assessment and non-invasive ventilation
- Quality statement 3: Provision of equipment and adaptions based on multidisciplinary team assessment
- Quality statement 4: Continuity of care
- Quality statement 5: Planning for end of life care
- About this quality standard
This quality standard covers care and support for older people living in their own homes (known as home care or domiciliary care). It covers people aged over 65 using home care services, and may also cover some people under 65 with complex needs. It describes high-quality care in priority areas for improvement.
View quality statements for QS123Show all sections
Sections for QS123
- Quality statements
- Quality statement 1: Person-centred planning
- Quality statement 2: Plan for missed or late visits
- Quality statement 3: Consistent team of home care workers
- Quality statement 4: Length of home care visits
- Quality statement 5: Reviewing the outcomes of the home care plan
- Quality statement 6: Supervision of home care workers
- About this quality standard
This quality standard covers managing medicines safely and effectively in care homes. It includes processes for prescribing, handling and administering medicines for adults, young people, and children living in care homes. It also includes providing care and support relating to medicines. It describes high-quality care in priority areas for improvement.
View quality statements for QS85Show all sections
Sections for QS85
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.
Evidence-based recommendations on PeritX for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites.
The MIST Therapy system for the promotion of wound healing (HTG267)
Evidence-based recommendations on the MIST Therapy system for the promotion of wound healing.